Trial Profile
Single dose pharmacokinetic study of HP-3060 in pediatric patients with allergic rhinitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2017
Price :
$35
*
At a glance
- Drugs Emedastine (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Hisamitsu Pharmaceutical
- 12 Sep 2017 Status changed from recruiting to completed.
- 15 Jun 2016 New trial record